← Back to Search

Checkpoint Inhibitor

V941 for Tumors

Phase 1
Waitlist Available
Research Sponsored by Merck Sharp & Dohme Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 25 months
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat cancer.

Eligible Conditions
  • Tumors
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
  • Colorectal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 25 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 25 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Dose-Limiting Toxicities (DLTs)
Number of Participants Who Discontinued Study Treatment Due to an AE
Number of Participants Who Experienced an Adverse Event (AE)
Secondary outcome measures
Mutant KRAS Specific T cells
Objective Response Rate (ORR)
Other outcome measures
T-cell receptor (TCR)

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

Trial Design

2Treatment groups
Experimental Treatment
Group I: V941 MonotherapyExperimental Treatment1 Intervention
V941(mRNA-5671/V941) administered intramuscularly (IM) once every 3 weeks (Q3W) for 9 3-week cycles
Group II: V941 + PembrolizumabExperimental Treatment2 Interventions
V941(mRNA-5671/V941) administered IM Q3W for 9 cycles and pembrolizumab 200 mg, intravenous (IV) for 35 3-week cycles
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
V941
2019
Completed Phase 1
~70
Pembrolizumab
2017
Completed Phase 2
~2010

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor
2,286 Previous Clinical Trials
4,581,758 Total Patients Enrolled
5 Trials studying Tumors
149 Patients Enrolled for Tumors
Merck Sharp & Dohme LLCLead Sponsor
3,886 Previous Clinical Trials
5,054,483 Total Patients Enrolled
11 Trials studying Tumors
2,324 Patients Enrolled for Tumors
Medical Director, MDStudy DirectorMerck Sharp & Dohme Corp.
76 Previous Clinical Trials
16,174 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
2019. "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03948763.
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top